Prognosis
Trump’s Options to Cap Drug Prices Wane After Rebate Retreat
- White House turn boosts benefit managers as pharma stocks fall
- Azar says administration weighing importation of cheaper drugs
This article is for subscribers only.
The Trump administration’s options for lowering high prescription-drug costs are narrowing after the White House decided to abandon a proposal that would have saddled seniors with higher health costs.
Drugmakers frequently give pharmacy-benefit managers discounts in the form of rebates to win coverage for their medicines. But as anger over soaring drug costs simmered, pharmaceutical companies have complained that PBMs often pass little of the savings from rebates directly to patients with the highest costs..